### 1 CRISPR-based editing strategies to rectify *EYA1* complex genomic 2 rearrangement linked to haploinsufficiency

- 3 Yi Hwalin<sup>1,7</sup>, Yejin Yun<sup>2,7</sup>, Won Hoon Choi<sup>2,7</sup>, Hye-Yeon Hwang<sup>1,7</sup>, Ju Hyuen Cha<sup>2</sup>,
- 4 Heeyoung Seok<sup>3</sup>, Jae-Jin Song<sup>4</sup>, Jun Ho Lee<sup>2</sup>, Seung Ha Oh<sup>2</sup>, Sang-Yeon Lee<sup>2,5,6\*</sup>,
- 5 Daesik Kim<sup>1\*</sup>
- <sup>6</sup> <sup>1</sup>Department of Precision Medicine, Sungkyunkwan University School of Medicine,
- 7 Suwon 16419, Republic of Korea
- <sup>8</sup> <sup>2</sup>Department of Otorhinolaryngology, Seoul National University College of Medicine,
- 9 Seoul National University Hospital, Seoul 03080, South Korea
- <sup>10</sup> <sup>3</sup>Department of Transdisciplinary Research and Collaboration, Genomics Core
- 11 Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul
- 12 03080, South Korea
- <sup>13</sup> <sup>4</sup>Department of Otorhinolaryngology, Seoul National University College of Medicine,
- 14 Seoul National University Bundang Hospital, Seongnam
- <sup>5</sup>Department of Genomic Medicine, Seoul National University Hospital, Seoul 03080,
- 16 Republic of Korea
- <sup>17</sup> <sup>6</sup>Sensory Organ Research Institute, Seoul National University Medical Research
- 18 Center, Seoul 03080, Republic of Korea
- <sup>7</sup>These authors contributed equally.
- <sup>20</sup> \*Correspondence should be addressed to D.K. (dskim89@skku.edu) and S-Y.L.
- 21 (maru4843@hanmail.net)

### 23 Abstract

24 Pathogenic structure variations (SVs) and genomic rearrangements are associated with various types of cancer and rare genetic diseases. Recent studies have used 25 26 Cas9 nuclease with paired guide RNAs (gRNAs) to generate targeted chromosomal 27 rearrangements. Studies on Cas9-mediated translocations and inversions have 28 mainly focused on producing fusion proteins that cause cancer, whereas research on 29 precision genome editing for rectifying SVs is limited. In this study, through whole-30 genome sequencing, we identified a novel complex genomic rearrangement (CGR), 31 specifically an EYA1 inversion with a deletion, implicated in branchio-oto-32 renal/branchio-oto (BOR/BO) syndrome. The CGR results in a loss-of-function allele, 33 leading to haploinsufficiency. To address this, two CRISPR-based editing approaches were tested. First, we engineered Cas9 nuclease and paired gRNAs 34 35 tailored to the patient's genome. The dual CRISPR/Cas9 system induced efficient 36 editing at sites with paracentric inversion in patient-derived fibroblasts (up to 1.6%), 37 and effectively restored the expression levels of the EYA1 gene and its downstream 38 targets, restoring overall transcriptional functionality. Additionally, we engineered 39 gene-activating CRISPR-Cas modules (CRISPRa), which increased EYA1 mRNA 40 and protein expression to wild-type levels in human EYA1 monoallelic knockout cells 41 that mimic the haploinsufficiency. Moreover, CRISPRa significantly improved 42 transcriptional activity essential for target gene expression. This suggests that 43 CRISPRa-based gene therapies may offer substantial translational potential for 44 approximately 70% EYA1 variants of disease-causing responsible for 45 haploinsufficiency. In parallel to deciphering the complexities of the genomic

- 46 landscape related to human genetic disorders, our findings demonstrate the potential
- 47 of CIRSPR-guided genome editing for correcting SVs, including those with EYA1
- 48 CGR linked to haploinsufficiency.

### 49 Introduction

50 Pathogenic structure variations (SVs) and genomic rearrangements are observed in various types of cancer and rare genetic diseases<sup>1</sup>. Genomic rearrangements are 51 52 alterations in the architecture of genomic DNA that can result in complex structures such as inversions, deletions, duplications, and translocations<sup>1</sup>. These genomic 53 54 rearrangements can arise from DNA double-strand breaks (DSBs) and incorrect rejoining of the DNA ends via mechanisms such as non-allelic homologous 55 recombination and non-homologous end joining<sup>1</sup>. Chromosome microarrays and 56 57 multiplex ligation-dependent probe amplification (MLPA) have become routine realworld techniques for detecting abnormal copy numbers<sup>2</sup>, but genomic approaches 58 59 cannot identify balanced SVs, such as inversions and translocations. With the diagnostic and technical availability of whole-genome sequencing (WGS), a range of 60 SVs, including complex genomic rearrangements (CGRs), can be identified at a 61 much higher resolution than previously<sup>3</sup>, which leads to a better understanding of 62 63 their mechanisms and potential therapeutic targets.

64 The CRISPR/Cas9 system has been adapted for site-specific genome editing in diverse cell types and model organisms<sup>4,5</sup>. Cas9 nuclease generates a 65 66 DNA DSB at target sites, which induces the cellular repair process through either homology-directed repair or non-homologous end-joining (NHEJ) pathways. The 67 development of advanced CRISPR nuclease using paired guide RNAs (gRNAs) 68 achieves precise targeted gene deletions and replacement in human cells<sup>6</sup>. 69 70 Furthermore, recent studies have used Cas9 nuclease in combination with paired 71 gRNAs to generate targeted chromosomal rearrangements, focusing on cancer-

associated chromosomal rearrangements such as *EML4-ALK*, *NPM-ALK*, *CD74- ROS1*, *KIF5B-RET*, *EWSR1-FLI1*, and *AML1-ETO*<sup>7-10</sup>. Previous studies have
primarily focused on generating fusion proteins implicated in cancer, whereas the
field of precise genome editing for correcting SVs requires further exploration.

76 Through WGS, we identified a novel CGR, characterized by an EYA1 77 inversion with a deletion, responsible for branchio-oto-renal/branchio-oto (BOR/BO) 78 syndrome. The CGR mutation results in a loss-of-function allele and thus 79 haploinsufficiency served as the underlying mechanism. To rectify this, we developed 80 two genome editing approaches. The Cas9 nuclease and paired gRNAs precisely 81 induce the paracentric inversion to correct the CGR mutation with relatively high 82 efficiency in patient-derived fibroblasts. This dual CRISPR/Cas9 system successfully restores the expression level of the EYA1 gene, coupled with the expression of 83 84 downstream target genes, leading to an improvement in transcriptional activity. In 85 addition, through CRISPR activator (CRISPRa) with a versatile therapeutic profile, 86 the expression level of both the EYA1 gene and its encoded protein were increased 87 similar to wild-type levels in human EYA1 monoallelic knockout cells that mimic 88 haploinsufficiency. The CRISPRa system significantly improved transcriptional 89 activity essential for target gene expression, suggesting such advancements might 90 be relevant to all disease-causing variants associated with EYA1 haploinsufficiency.

### 91 Materials and methods

### 92 Participants

93 All procedures were approved by the Institutional Review Board of Seoul National 94 University Hospital (IRB-H-0905-041-281 and IRB-H-2202-045-1298). In this study, 95 one BOR/BO multiplex family segregated with CGR was included in the Hereditary 96 Hearing Loss Clinic within the Otorhinolaryngology division of the Center for Rare 97 Diseases, Seoul National University Hospital, Korea. The demographic data and clinical phenotypes were retrieved from electronic medical records. The presence 98 99 and severity of associated medical conditions were determined using the Tenth 100 Revision of the International Statistical Classification of Diseases and Related Health 101 Problems (ICD-10) codes and/or features in their clinical manifestations.

102

### 103 Whole-exome sequencing and Multiplex Ligation-dependent Probe104 Amplification

105 Genomic DNA was extracted from peripheral blood samples and used in whole-106 exome sequencing (WES) via SureSelectXT Human All Exon V5 (Agilent 107 Technologies, Santa Clara, CA, USA). Adhering to the instructions provided, we 108 prepared a library which was then sequenced using a NovaSeq 6000 system 109 (Illumina, San Diego, CA, USA) in a paired-end manner. Sequence reads were compared to the human reference genome (GRCh38) and processed in line with the 110 Genome Analysis Toolkit best-practice guidelines to identify single nucleotide 111 variants (SNVs) and indels<sup>11</sup>. The ANNOVAR program was used for variant 112

annotation, such as from the RefSeq gene set and gnomAD<sup>12,13</sup>. Rare non-silent variants were selected as candidates, including nonsynonymous SNVs, coding indels, and splicing variants. We also used the KRGDB and KOVA databases for further filtration of ethnic-specific variants<sup>14,15</sup>. We conducted a comprehensive bioinformatics analysis to detect candidate variants using a defined filtering process, as described previously<sup>16-18</sup>.

We also assessed the copy number status of *EYA1* using a SALSA Multiplex Ligation-dependent Probe Amplification (MLPA) P461 DIS Probemix kit (MRC-Holland, Amsterdam, Netherlands). The amplification products were analyzed with an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), and the results were interpreted with the aid of Gene Marker 1.91 software (SoftGenetics, State College, PA, USA).

125

### 126 Whole-genome sequencing and bioinformatics

127 Genomic DNA was extracted from peripheral blood samples using Allprep DNA/RNA 128 kits (Qiagen, Venlo, Netherlands) and libraries were generated with TruSeg DNA 129 PCR-Free Library Prep Kits (Illumina). The libraries were then sequenced on the 130 Illumina NovaSeq6000 platform with the coverage set at an average depth of 30x. 131 The obtained sequences were aligned to the human reference genome (GRCh38) 132 using the BWA-MEM algorithm and PCR duplicates were eliminated using 133 SAMBLASTER. Mutation calling for base substitutions and short indels was achieved with HaplotypeCaller2 and Strelka2, respectively. Delly was used to identify 134 135 SVs. The breakpoints of the genomic rearrangements of interest were visually

136 examined and validated. Variant filtering and assessment of their Mendelian 137 inheritance patterns were carried out. The pathogenicity of the variants was 138 classified the using American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines<sup>19</sup>. 139

140

### 141 Cell culture and transfection

Patient fibroblasts were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin/amphotericin. To induce the correction of pathogenic inversion,  $2 \times 10^5$  patient fibroblasts were transfected with 17 µg Cas9 protein, 5 µg of in vitro transcribed gRNA targeting the A-B junction, and 5 µg of in vitro transcribed gRNA targeting the B-C junction using an Amaxa P3 Cell Line 4D-Nucleofector Kit (CM-137 program). Cells were analyzed 3 days after transfection.

HEK293T cells (American Type Culture Collection, ATCC, CRL-11268) were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For dCas9-VP64 mediated *EYA1* activation, HEK293T cells were seeded onto 24-well plates and transfected with 2,000 ng of plasmid DNA encoding dSaCas9-VP64 and gRNA (Addgene plasmid #158990) using 3 μL Lipofectamine 2000 (Life Technologies). After 72 h, total RNA was isolated with an RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions.

155

### 156 Targeted deep sequencing

157 Genomic DNA containing the on-target was amplified using KAPA HiFi HotStart DNA

polymerase. The amplified products were designed to include Illumina TruSeq HT dual index adapter sequences. Subsequently, the amplified products were subjected to 150-bp paired-end sequencing using the Illumina iSeq 100 platform. To calculate the frequencies of insertions and deletions (indels), we used the MAUND tool, which is available at <u>https://github.com/ibs-cge/maund</u>.

163

### 164 Digital droplet PCR

165 Molecular analysis of the CGR derived from WGS was conducted using breakpoint 166 PCR and digital droplet PCR (ddPCR). Genomic DNA extracted from patients was 167 used to perform ddPCR with the QX200 ddPCR system (Bio-Rad). Procedures 168 followed the manufacturer's protocol with minor modifications. Briefly, the master mix 169 for ddPCR consisted of 100 ng of genomic DNA, 1×ddPCR supermix for probes (no 170 dUTP; 186-3023, Bio-Rad), 1.0 µM primer, and 0.25 µM probe (Metabion, 171 Germany). Primers and a probe were designed for EYA1 breakpoint junctions 172 (Supplementary Table 1). The samples were thoroughly combined before being put 173 into a Bio-Rad QX100/QX200 droplet generator's DG8 cartridge. The cartridge was 174 then put into the QX200 Droplet Generator (Bio-Rad) and Droplet Generation Oil 175 was added. After droplet formation, the droplets were carefully moved to a twin-tec 176 semi-skirted 96-well PCR plate (EP0030128575, Eppendorf). PCR was then carried 177 out in a C1000 Touch thermal cycler (Bio-Rad) for the two-step running program of 178 94 °C for 30s and 56 °C for 1min for 40 cycles with an initial and final incubation at 179 95 °C and 98 °C, respectively. The signal in each droplet was read by using a droplet 180 reader and analyzed using the QuantaSoft program (Version 1.7, Bio-Rad).

181

### 182 RNA isolation and real-time quantitative PCR

183 Total RNA (1 µg) was extracted from either fibroblasts or HEK293T cells using the 184 TRIzol method, with subsequent purification via Rneasy mini-columns (Qiagen) and 185 an incorporated on-column Dnase I treatment. The synthesis of cDNA was achieved 186 from 2 µg of the isolated total RNA using the reverse transcription (RT)-PCR method 187 and Accupower RT-pre-mix (Bioneer). Quantitative RT-PCR assays were performed 188 on cDNA samples diluted 1/20 using SYBR qPCR master mix (Kapa Biosystems, 189 USA) as the reporter dye. Primers at a concentration of 10 pmol were used to detect 190 specific gene mRNA expression. Their sequences were as follows: SOX2, forward 191 5'-GCTACAGCATGATGCAGGACCA-3' and 5'reverse 192 TCTGCGAGCTGGTCATGGAGTT-3'; NEUROG1, forward 5′-193 GCCTCCGAAGACTTCACCTACC-3' and reverse 5'-GGAAAGTAACAGTGTCTACAAAGG-3'; GFI1, 5′-194 forward 195 GCTTCAAGAGGTCATCCACACTG3' and reverse 196 ACCTGGCACTTGTGAGGCTTCT-3'; and GAPDH, forward 5'-197 GAGTCAACGGATTTGGTCGT-3' and reverse 5'- GACAAGCTTCCCGTTCTCAG-3'. 198 The primer sequences for EYA1 can be found in the Supplementary tables. The 199 relative frequency of EYA1 mRNA was determined using the comparative  $C_{T}$  method 20 200

201

### 202 Luciferase reporter gene assay

The luciferase reporter gene assay was performed, as described previously with slight modifications<sup>17</sup>. Briefly, HEK293T cells were transfected initially with three distinct plasmids: pGL4.12[luc2CP]-MYOG-6xMEF3, pRK5-SIX1, and pRL/CMV (E2261, Promega). Post-transfection, the cells were harvested for a luciferase assay using a Dual-Luciferase Reporter Assay kit (E1910, Promega), following the manufacturer's guidelines. Transfection efficiency was adjusted based on Renilla activity, which was assessed after co-transfection with pRL/CMV.

210

### 211 Generating single cell-derived EYA1 knockout clones

212 HEK293T cells were maintained in DMEM supplemented with 10% FBS and 1% 213 penicillin-streptomycin. For the transfection, the cells were seeded in 24-well plates 214 and co-transfected with 1500 ng of the Cas9 expression plasmid and 500 ng of a (5'-215 sgRNA-encoding plasmid containing а spacer sequence 216 ATGCCACGTACCCACAGCC-3' the strand 5'on top and 217 GGCTGTGGGTACGTGGCAT-3' on the bottom strand). Single-cell clones were 218 generated via limiting dilutions in 96-well plates, followed by clonal expansion. 219 Genomic DNA from these clones was isolated using Allprep DNA/RNA kits (Qiagen) 220 according to the manufacturer's instructions, and mutation frequencies were 221 determined through targeted deep sequencing.

222

### 223 Immunoblotting

224 Cells were washed with PBS and lysed using RIPA buffer supplemented with

225 protease inhibitors. The lysates combined with sample buffer were denatured at 226 85°C in preparation for SDS-PAGE. Subsequently, proteins were transferred to 227 polyvinylidene difluoride (PVDF) membranes. Membranes were blocked in 5% 228 nonfat milk in TBS-T and then probed with primary antibodies. After comprehensive 229 washing, membranes were exposed to horseradish peroxidase-linked secondary 230 antibodies, specific to rabbit or mouse IgG. Protein bands became evident upon 231 chemiluminescence application and were subsequently imaged. Band intensities 232 were quantified using ImageJ software based on replicated experiments. Statistical 233 evaluation was conducted using GraphPad Prism V5. Results with a p-value < 0.05were used to confirm significance. Sources of antibodies and working dilutions were 234 235 as follows: beta-actin, anti-β-actin (A1978, Sigma, 1/10,000); anti-EYA1 (22658-1-AP, 236 Proteintech, 1/1,000).

### 237 Results

### 238 Identification of a novel complex genomic rearrangement in the EYA1 gene

239 The proband, mother of the proband and affected siblings in SNUH family exhibited 240 a range of clinical phenotypes associated with BOR/BO syndrome, demonstrating 241 complete penetrance but variable expressivity of clinical phenotypes (Figure 1a). A 242 bioinformatics approach and filtering strategy of WES results, aimed at prioritizing 243 candidate causal variants for BOR/BO syndrome, yielded negative results. The 244 sequential MLPA test showed a normal copy number state in EYA1 (Supplementary 245 Figure 1). A thorough examination of a region on chromosome 8 was conducted by 246 leveraging SV profiles via family-based WGS. This process revealed a novel CGR 247 involving an EYA1 inversion (g.71211857 to g.71228236; with a 5'-breakpoint in 248 intron 16 of EYA1 and a 3'-breakpoint in intron 12 of EYA1, with a deletion at the 249 end of the segment (g.71211857 to g.71215145; with both the 5'-breakpoint and 3'-250 breakpoint located in intron 16) (Figure 1b and Supplementary Figure 2). We 251 identified two neo-junctional reads, one with 1 bp of microhomology (A-B, 252 g.71215145) and the other with 2 bp of microhomology (B-C, g.71228236) 253 (Supplementary Figure 3). To confirm the breakpoint junctions identified by WGS, 254 we designed four pairs of forward and reverse primers (Supplementary Table 1). 255 Gap-PCR revealed the amplification of a 954-bp PCR product corresponding to the 256 breakpoint within intron 16 (A-B junction) and a 235-bp PCR product corresponding 257 to the breakpoint within intron 12 (B-C junction) (Figure 1c). We also verified the 258 genomic sequence of junctions by Sanger sequencing (Figure 1c). The CGR in 259 EYA1 results in a frameshift variant, leading to a premature stop codon at codon CTA

within exon 16. This stop codon results in a truncated non-functional protein that lacks 210 amino acids at the C-terminal end, a region that includes the functional EYA domain (**Figure 1d**).

263

### 264 Cas9 nuclease with paired gRNAs induce efficient editing at sites of the 265 paracentric inversion

266 To assess the potential of Cas9 nucleases with paired gRNA for correcting the 267 pathogenic inversion in patient-derived fibroblasts (Figures 2a and 2b), we designed 268 gRNAs that specifically target the junction sites between fragment A and the inverted 269 B (13 kb) fragment, as well as between the inverted B (13 kb) and C fragments 270 (Figure 2c). We transfected patient fibroblast cells with complexes of Cas9 protein 271 and *in vitro* transcribed gRNAs targeting the fragment junctions (Figure 2c), and 272 measured editing frequencies using targeted deep sequencing (Figure 2d). The 273 editing efficiency at target sites AB-T1 and AB-T2, located at the junction between 274 fragment A and the inverted B (13 kb) fragment (A-B junction), were found to be 36.9% 275 and 1.9%, respectively. Similarly, the Cas9 nuclease targeting the junctions between 276 the inverted B (13 kb) fragment and fragment C (B-C junction) at sites BC-T1, BC-T2, 277 and BC-T3 showed editing efficiencies of 57.2%, 89.0%, and 78.6%, respectively. 278 Based on these results, we selected Cas9 nucleases targeting either AB-T1 and BC-279 T2 or AB-T1 and BC-T3 to induce the correction of the pathogenic inversion.

We next investigated whether Cas9 nuclease with paired gRNAs could correct the pathogenic inversion between endogenous loci in patient-derived fibroblasts (**Figure 2a**). To induce a paracentric inversion between the A-B junction and B-C

283 junction, we co-transfected Cas9 protein and paired gRNAs targeting the two 284 junctions. We then amplified the expected inversion junctions with paracentric 285 inversion-specific primer pairs and found that inversions were induced in cells 286 transfected with Cas9 protein and paired gRNAs (Figure 2e). To further analyze 287 these amplicons, we performed targeted deep sequencing and found that Cas9 288 nuclease could induce a paracentric inversion that corrects the pathogenic inversion 289 with additional small insertions or deletions (indels) at the junctions in patient-derived 290 fibroblast cells (Figure 2f). To measure the inversion frequencies induced by Cas9 nuclease and paired gRNAs, we used dilution PCR<sup>21,22</sup>. Through this analysis, we 291 292 observed that the inversion frequency induced by Cas9 nuclease and paired gRNAs 293 was up to 1.6% in patient-derived fibroblast cells (Figure 2g). These results 294 demonstrate that Cas9 nuclease and paired gRNAs, which are specific to the 295 patient's genome, can correct the pathogenic inversions with relatively high efficiency 296 in patient-derived fibroblasts.

297

298 Cas9 nuclease with paired gRNAs restores *EYA1* expression and 299 transcriptional activity

We assessed whether the Cas9 nuclease with paired gRNAs could restore the variant allele frequency (VAF) of the inversion junctions in patient cells using ddPCR (**Figure 3a**). We designed a primer/probe set that targeted both reference and mutated gene sequences at the A-B and B-C breakpoint junctions (**Figure 3b**). The VAF of the A-B and B-C junctions compared to the reference gene in patient fibroblast cells were 0.507 and 0.488, respectively. Notably, in the edited cells in

which the AB-T1 and BC-T2 sites were targeted, the VAF of the A-B and B-C 306 307 junctions decreased to 0.381 and 0.181, respectively. Similarly, the ratios dropped to 308 0.392 and 0.233 when AB-T1 and BC-T3 were targeted (Figure 3c). To verify that 309 the genome editing elicited a recovery of the EYA1 transcript, we conducted 310 quantitative reverse transcription PCR (gRT-PCR) with a primer set that covered the 311 breakpoint junctions (Supplementary Table 3). Targeting both combinations of sites 312 (AB-T1 with BC-T2 and AB-T1 with BC-T3) led to a significant increase in the 313 amount of wild-type EYA1 transcripts (fig. 3d). To assess the potential restoration of 314 the EYA1 transcriptional activity, we used a luciferase assay (Figure 3e). EYA1 315 encodes a transcriptional coactivator; the Eya domain is crucial for the formation of 316 the EYA1-SIX1-DNA complex that regulates the transcription of target genes involved in the development of the branchial arch, otic system, and renal system<sup>23</sup>. In 317 318 this context, we used the pGL4.12[luc2CP]-MYOG-6xMEF3 construct, which 319 incorporates a luciferase reporter along with six repeats of the MEF3 motif. 320 Importantly, each motif exhibits a specific affinity for the EYA1 and SIX1 protein 321 complex. Under the conditions of SIX1 overexpression, we observed that the 322 luciferase activity in the EYA1 mutant significantly decreased to 12.7% of the wild-323 type levels, representing a 7.8-fold reduction. On the other hand, cells with edited 324 genes displayed a substantial increase in luciferase activity relative to the mutant, 325 with increases of 2.7-fold at the AB-T1 and BC-T2 sites, and 3.4-fold at the AB-T1 326 and BC-T3 sites. These levels correspond to 34.1% and 43.8%, respectively, of 327 those observed in control cells. Although it is essential to investigate the downstream 328 target gene expression and the modifications in the transcriptome tied to EYA1 329 transcriptional activity, our data suggest that the dual Cas9 nucleases, designed to

specifically target the paracentric inversion in the patient genome, are capable ofrestoring the transcriptional functionality of *EYA1*.

In the literature, *EYA1* CGRs involving inversions and deletions have been well-documented in BOR/BO cases<sup>24,25</sup>. Consistent with this, our in-house database revealed that two unrelated BOR/BO families were segregated with CGRs (**Supplementary Figure 2**), including a cryptic large inversion, accounting for 18% (**Supplementary Table 4**). Thus, the dual CRISPR/Cas9 system developed herein has the potential to correct pathogenic SVs, including those with *EYA1* CGRs, implicated in human genetic disorders.

339

### 340 **Development of EYA1 CRISPR activator for haploinsufficiency**

341 The pathogenic inversion occurring in the EYA1 leads to nonsense-mediated mRNA 342 decay, resulting in haploinsufficiency (Figures 1d and 3d). Notably, when the cells 343 were treated with cycloheximide (CHX), stabilization of the EYA1 transcript was 344 observed, suggesting that the haploinsufficiency of EYA1 is dependent on NMD 345 (Figure 4a). To investigate the potential of CRISPRa for inducing increased 346 endogenous EYA1 expression, we transfected plasmid DNA encoding dSaCas9-347 VP64 and gRNA targeting the EYA1 promoter into HEK293T cells and compared the 348 relative expression of EYA1 mRNA in treated cells and control cells (Figure 4b). 349 Using qRT-PCR, we observed that dSaCas9-VP64 led to a substantial 4.0-fold 350 upregulation of EYA1 mRNA expression compared to untreated HEK293T cells. To 351 model the potential haploinsufficiency originating from a variety of mechanisms and 352 to evaluate the performance of the CRISPRa, we engineered HEK293T cells with

353 either monoallelic or biallelic knockouts of EYA1 (Figure 4c). We then investigated 354 whether co-expressing dSaCas9-VP64 with either gRNA2 or 3 affected the mRNA 355 expression of EYA1 in these cell lines. Quantitative assessments of relative mRNA 356 abundances indicated marked increases in wild-type and monoallelic knockout cells, 357 with up to 3.7 and 1.4-fold increases, respectively, when compared to untreated cells. 358 In contrast, cells with biallelic knockouts exhibited no discernible alterations in mRNA 359 levels (Figure 4d). We further analyzed transcriptional activity of EYA1 through a 360 luciferase-based reporter gene assay, aiming to assess the potential restoration of EYA1 functionality with CRISPRa (Figure 4e). Under normal conditions, the 361 362 luciferase activity in both monoallelic and biallelic knockout cells showed substantial 363 reductions, by 68.5% and 64.4%, respectively, compared to HEK293T cells. 364 Conversely, cells subjected to CRISPRa had enhanced luminescence, with 365 increases of 1.3-fold in HEK293 cells and 1.7-fold in monoallelic knockout cells 366 relative to their untreated counterparts. Consistent with the results of mRNA levels, 367 biallelic knockout cells were not affected by CRISPRa. In line with these 368 observations, protein levels in CRISPRa-treated cells increased by 1.84-fold in 369 HEK293T cells and 8.00-fold in monoallelic knockout cells (Figure 4f).

In the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/), we noted that 81 disease-causing *EYA1* variants (pathogenic or likely pathogenic) were implicated in BOR/BO syndrome (**Figure 5a and Supplementary Table 5**). The majority (68%) of the documented *EYA1* variants with BOR/BO phenotypes were loss-of-function, including nonsense, frameshift, canonical splicing, and SVs, resulting in haploinsufficiency (**Figure 5b**). Our results indicate that CRISPRa holds potential as

- a versatile genome editing approach to address EYA1 haploinsufficiency, including
- 377 those involving CGRs, suggesting its significance for personalized genome-specific
- 378 interventions.

### 379 Discussion

380 This study highlights the importance of SVs, including CGRs and inversions, in rare 381 diseases<sup>1,26</sup>. In the literature, various genomic rearrangements, such as cryptic 382 inversions and large deletions, have been well-documented in approximately 20% of BOR/BO cases<sup>24,27</sup>. In certain cases, not only EYA1 but also other genes were found 383 to be involved, resulting in BOR/BO syndrome with additional clinical phenotypes<sup>27</sup>. 384 385 Furthermore, non-allelic homologous recombination and human endogenous 386 retrovirus elements are known to induce recurrent genomic rearrangements associated with BOR/BO syndrome<sup>28,29</sup>. The advancement of genomic technologies, 387 388 coupled with reduced sequencing costs and improved data management, has made 389 extraordinary strides toward deciphering the complex genetic architecture underlying human genetic disorders<sup>30,31</sup>. In parallel with this, precision genome editing 390 391 approaches tailored to the patient's genome facilitate the recovery of transcriptional 392 activity vital for target gene expression. Therefore, we believe that the dual 393 CRISPR/Cas9 system or CRISPRa-based gene therapy could have the potential to 394 expand the treatment landscape for human genetic disorders, even for pathogenic 395 SVs and CGRs.

Previous studies have shown the potential of targeted gene addition strategies as a therapeutic approach for Hemophilia A, which is often caused by pathogenic inversions of the *F8* gene<sup>32</sup>. This approach led to the restoration of *F8* expression in mesenchymal stem cells and endothelial cells, which had been differentiated from gene-corrected induced pluripotent stem cells (iPSCs)<sup>32</sup>. Moreover, Hu et al. provided a gene correction strategy for Hemophilia A, caused by

402 an F8 intron 1 large sequence inversion variant, through homology-mediated end joining with a high efficiency of 10.2%<sup>33</sup>. Genome editing using paired gRNAs has 403 404 demonstrated efficient genomic modifications across various preclinical studies and even extended to human trials in the treatment of ophthalmic diseases<sup>34</sup>. The human 405 406 trial used paired gRNAs to target and delete the aberrant splice donor site caused by 407 the CEP290 variant, which is commonly associated with Leber congenital amaurosis 408 type 10 (LCA10), suggesting the potential of a Cas9 nuclease and paired gRNA system for therapeutic genome editing in human genetic disorders<sup>34</sup>. Furthermore, 409 prime editing approaches that use paired pegRNAs (TwinPE)<sup>35</sup> and prime editor 410 nuclease-mediated translocation and inversion (PETI)<sup>7</sup> can facilitate programmable 411 412 genome editing in mammalian cells. These approaches utilize paired pegRNAs 413 oriented in a protospacer adjacent motif (PAM)-in configuration to structure 3' flaps 414 on opposing genetic strands. These strategies demonstrate variances in both the 415 synthesized flaps and the approaches used for DNA target incision<sup>35</sup>. Although 416 CRISPR-based genome editing technologies to correct inversion sequences are 417 evolving, there is a lack of published evidence on the therapeutic potential of Cas9 418 nuclease with paired gRNAs to target disease-causing paracentric inversions in 419 patient-derived cells.

420 Cas9-derived DNA DSBs at dual loci within the *EYA1* gene have the potential 421 to catalyze genomic rearrangements, as demonstrated by the paracentric inversion 422 editing event in this study. Mechanistically, the CRISPR-Cas9 system, when used 423 with paired gRNAs designed to target distinct genomic locations, has the potential to 424 yield diverse modifications in DNA<sup>36,37</sup>. The inversion generated by a dual

CRISPR/Cas9 system has been demonstrated across mammalian cell lines<sup>38,39</sup> as 425 well as *in vivo* in animal models<sup>40</sup>, suggesting the validity of the system in 426 427 engineering specific inversion mutations. Encouraged by these insights, we 428 hypothesize that paired gRNAs could be a potential therapeutic option to correct the 429 disease-causing CGRs implicated in BOR/BO syndrome. We successfully applied 430 the dual CRISPR/Cas9 system that specifically targeted a disease-causing 431 paracentric inversion in patient-derived cells. The system demonstrated significant 432 editing efficiency, leading to the restoration of significant gene expression and 433 associated transcriptional functionality. Considering that an editing efficiency of even 434 1-2% in primary cells using CRISPR/Cas9 nuclease has been shown to rescue the hearing function of mice with Atp2b2 mutations<sup>41</sup>, the 1.6% editing efficiency we 435 436 achieved in patient-derived fibroblasts is particularly noteworthy. This result raises 437 the possibility of restoring disease phenotypes, such as hearing impairment, in 438 BOR/BO patients with EYA1 CGRs including paracentric inversion.

439 Understanding the mechanistic pathways has the potential to significantly 440 expand the therapeutic applications of the dual CRISPR/Cas9 system in clinical 441 settings. When the Cas9 nuclease does not simultaneously cleave at both target 442 sites, it instigates a sequence of events that leads to the accumulation of mutations 443 around the gRNA target regions, which is attributed to the cellular repair mechanisms NHEJ and microhomology-mediated end joining <sup>42</sup>. Alternatively, when Cas9 444 445 nucleases simultaneously cleave at both target loci the subsequent ligation could 446 induce a large deletion, inversion, or translocation of the genomic fragment 447 intervening between the target sites. Documented instances of such inversions

suggest a scenario where both sgRNAs interact with the Cas protein, forming a single complex capable of excising gene segments<sup>43</sup>. This process facilitates the complex in generating a nick in both sgRNAs, thereby presenting three potential pathways for DNA repair. These include small indels, large deletion, substantial deletions, or inversions<sup>44</sup>. More specifically, it is plausible to posit that the formation of an inversion concurrently negates PAM sites and excises a fraction of the sgRNAs, liberating the cleavage sites<sup>43</sup>.

455 CRISPRa utilizes a Cas9 variant, dCas9, which lacks nuclease activity, 456 combined with a transcriptional activator. By targeting the EYA1 promoter, the 457 dCas9-VP64 fusion used in our CRISPRa system increases EYA1 expression (see 458 Figure 4b), leading to significantly improved transcriptional activity essential for 459 target gene expression. Of the documented EYA1 variants linked with BOR/BO phenotypes, approximately 70% are described as monoallelic loss-of-function 460 461 variants, including nonsense, frameshift, canonical splicing, and SVs (see Figure 462 **5b**). As a consequence, there is a state of haploinsufficiency. This suggests that 463 CRISPRa-based gene therapies may offer substantial translational potential for 464 approximately 70% of disease-causing EYA1 variants caused by haploinsufficiency.

In conclusion, our results pave the way for the potential development of gene editing therapeutics for the clinical application of human genetic disorders caused by pathogenic SVs such as inversion and genomic rearrangements. In particular, BOR/BO syndrome stands as a representative case where hearing impairment is the most penetrant symptom<sup>17,45</sup>. Most branchial anomalies associated with this syndrome can be managed surgically, and the renal phenotype is rare. The inner ear

471 presents a particularly promising target for gene therapy due to its low 472 immunogenicity and compact enclosed structure that facilitates localized intervention. 473 Previous studies have highlighted the efficacy of adeno-associated virus (AAVs) in 474 transducing overexpressed cDNA and gene editing materials into target cells within the inner ear<sup>46,47</sup>. The advancements in gene editing technologies, including dual 475 476 CRISPR/Cas9 system and CRISPRa, could expand the therapeutic landscape 477 related to human genetic disorders, and encompass conditions such as BOR/BO 478 syndrome due to EYA1 CGRs associated with haploinsufficiency.

### 479 Acknowledgments

480 This research was supported and funded by SNUH Kun-hee Lee Child Cancer & 481 Rare Disease Project, Republic of Korea (FP-2022-00001-004 to S-Y. Lee), National 482 Research Foundation of Korea (NRF) and funded by the Ministry of Education (grant 483 number: 2022R1C1C1003147 to Sang-Yeon Lee), SNUH Research Fund (04-2022-484 4010 to S-Y. Lee and 04-2022-3070 to S-Y. Lee), National Research Foundation of 485 Korea (2020R1A2C2101714 to D.K), Korean Fund for Regenerative Medicine 486 (KFRM) grant funded by the Korean government (Ministry of Science and ICT, 487 Ministry of Health & Welfare [21A0202L1-12 to D.K.]), and Korea Health Technology 488 R&D Project through the Korea Health Industry Development Institute (KHIDI), 489 funded by the Ministry of Health & Welfare, Republic of Korea (HI21C1314 and 490 HR22C1363 to D.K.).

### 491 References

- 492 1 Schuy, J., Grochowski, C. M., Carvalho, C. M. B. & Lindstrand, A. Complex 493 genomic rearrangements: an underestimated cause of rare diseases. Trends
- 494 Genet 38, 1134-1146 (2022). https://doi.org:10.1016/j.tig.2022.06.003
- 2 495 Os, P. G. E.-V. & Schouten, J. P. Multiplex Ligation-dependent Probe 496 Amplification (MLPA®) for the detection of copy number variation in genomic sequences. PCR Mutation detection protocols, 97-126 (2011). 497
- 498 3 Li, Y. et al. Structural variation in two human genomes mapped at single-
- nucleotide resolution by whole genome de novo assembly. Nat Biotechnol 29,
- 500 723-730 (2011). https://doi.org:10.1038/nbt.1904
- 501 Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in 4 502 adaptive bacterial immunity. Science 337, 816-821 (2012). 503 https://doi.org:10.1126/science.1225829
- 504 5 Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 505 823-826 (2013). https://doi.org:10.1126/science.1232033
- 506 6 Zheng, Q. et al. Precise gene deletion and replacement using the 507 CRISPR/Cas9 system in human cells. *Biotechniques* 57, 115-124 (2014). https://doi.org:10.2144/000114196 508
- 509 7 Kweon, J. et al. Targeted genomic translocations and inversions generated 510 using a paired prime editing strategy. Mol Ther 31, 249-259 (2023). 511 https://doi.org:10.1016/j.ymthe.2022.09.008
- 512 8 Choi, P. S. & Meyerson, M. Targeted genomic rearrangements using 513 CRISPR/Cas technology. Nature communications 5, 3728 (2014).

514	9	Torres, R. e	t al.	Engine	eering humar	tumour-associa	ted chron	nosomal
515		translocations	with	the	RNA-guided	CRISPR–Cas9	system.	Nature
516		communicatior	ns <b>5</b> . 3	964 (2	014).			

- 517 10 Ghezraoui, H. *et al.* Chromosomal translocations in human cells are 518 generated by canonical nonhomologous end-joining. *Molecular cell* **55**, 829-519 842 (2014).
- 520 11 Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: 521 the Genome Analysis Toolkit best practices pipeline. Curr Protoc **Bioinformatics** 43. 11 10 11-11 10 33 522 (2013).
- 523 https://doi.org:10.1002/0471250953.bi1110s43
- 524 12 Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from
   525 variation in 141,456 humans. *Nature* 581, 434-443 (2020).
   526 <u>https://doi.org:10.1038/s41586-020-2308-7</u>
- 527 13 Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of 528 genetic variants from high-throughput sequencing data. *Nucleic Acids Res* **38**,
- 529 e164 (2010). <u>https://doi.org:10.1093/nar/gkq603</u>
- Lee, J. *et al.* A database of 5305 healthy Korean individuals reveals genetic
  and clinical implications for an East Asian population. *Exp Mol Med* 54, 1862-

532 1871 (2022). <u>https://doi.org:10.1038/s12276-022-00871-4</u>

- Jung, K. S. *et al.* KRGDB: the large-scale variant database of 1722 Koreans
  based on whole genome sequencing. *Database (Oxford)* 2020 (2020).
  https://doi.org:10.1093/database/baz146
- Lee, S. Y. *et al.* Ramifications of POU4F3 variants associated with autosomal
   dominant hearing loss in various molecular aspects. *Sci Rep* 13, 12584

### 538 (2023). <u>https://doi.org:10.1038/s41598-023-38272-w</u>

- 539 17 Lee, S. et al. Phenotypic and molecular basis of SIX1 variants linked to non-
- 540 syndromic deafness and atypical branchio-otic syndrome in South Korea. *Sci*
- 541 *Rep* **13**, 11776 (2023). <u>https://doi.org:10.1038/s41598-023-38909-w</u>
- 542 18 Lee, S. Y. et al. Novel KCNQ4 variants in different functional domains confer
- 543 genotype- and mechanism-based therapeutics in patients with nonsyndromic
- 544 hearing loss. *Exp Mol Med* **53**, 1192-1204 (2021).
- 545 <u>https://doi.org:10.1038/s12276-021-00653-4</u>
- Richards, S. *et al.* Standards and guidelines for the interpretation of sequence
  variants: a joint consensus recommendation of the American College of
  Medical Genetics and Genomics and the Association for Molecular Pathology.
- 549 Genet Med **17**, 405-424 (2015). <u>https://doi.org:10.1038/gim.2015.30</u>
- Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the
  comparative C(T) method. *Nat Protoc* 3, 1101-1108 (2008).
  https://doi.org:10.1038/nprot.2008.73
- 553 21 Kweon, J. *et al.* Targeted genomic translocations and inversions generated 554 using a paired prime editing strategy. *Molecular Therapy* **31**, 249-259 (2023).
- Lee, H. J., Kim, E. & Kim, J.-S. Targeted chromosomal deletions in human cells using zinc finger nucleases. *Genome research* **20**, 81-89 (2010).
- Ruf, R. G. *et al.* SIX1 mutations cause branchio-oto-renal syndrome by
  disruption of EYA1-SIX1-DNA complexes. *Proc Natl Acad Sci U S A* 101,
  8090-8095 (2004). https://doi.org:10.1073/pnas.0308475101
- 560 24 Vervoort, V. S. *et al.* Genomic rearrangements of EYA1 account for a large 561 fraction of families with BOR syndrome. *Eur J Hum Genet* **10**, 757-766 (2002).

### 562 https://doi.org:10.1038/sj.ejhg.5200877

- 563 25 Schmidt, T. *et al.* Branchio-otic syndrome caused by a genomic 564 rearrangement: clinical findings and molecular cytogenetic studies in a patient
- 565 with a pericentric inversion of chromosome 8. Cytogenet Genome Res 142, 1-
- 566 6 (2014). <u>https://doi.org:10.1159/000355436</u>
- 567 26 Li, Y. *et al.* Patterns of somatic structural variation in human cancer genomes.
   568 *Nature* 578, 112-121 (2020). <u>https://doi.org:10.1038/s41586-019-1913-9</u>
- 569 27 Chang, E. H. *et al.* Branchio-oto-renal syndrome: The mutation spectrum in 570 EYA1 and its phenotypic consequences. *Human mutation* **23**, 582-589 (2004).
- 571 28 Chen, X. *et al.* Recurrent 8q13. 2-13.3 microdeletions associated with 572 Branchio-oto-renal syndrome are mediated by human endogenous retroviral 573 (HERV) sequence blocks. *BMC Medical Genetics* **15**, 1-8 (2014).
- Sanchez-Valle, A. *et al.* HERV-mediated genomic rearrangement of EYA1 in
  an individual with branchio-oto-renal syndrome. *American Journal of Medical Genetics Part A* **152**, 2854-2860 (2010).
- 577 30 Turro, E. *et al.* Whole-genome sequencing of patients with rare diseases in a 578 national health system. *Nature* **583**, 96-102 (2020).
- 579 31 Schuy, J., Grochowski, C. M., Carvalho, C. M. & Lindstrand, A. Complex 580 genomic rearrangements: an underestimated cause of rare diseases. *Trends* 581 *in Genetics* (2022).
- Wu, Y. *et al.* In situ genetic correction of F8 intron 22 inversion in hemophilia A
  patient-specific iPSCs. *Sci Rep* 6, 18865 (2016).
  https://doi.org:10.1038/srep18865
- 585 33 Hu, Z. et al. Correction of F8 intron 1 inversion in hemophilia A patient-specific

- iPSCs by CRISPR/Cas9 mediated gene editing. *Front Genet* 14, 1115831
   (2023). https://doi.org:10.3389/fgene.2023.1115831
- Maeder, M. L. *et al.* Development of a gene-editing approach to restore vision
  loss in Leber congenital amaurosis type 10. *Nat Med* 25, 229-233 (2019).
- 590 <u>https://doi.org:10.1038/s41591-018-0327-9</u>
- 591 35 Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome
  592 manipulation. *Nat Rev Genet* 24, 161-177 (2023).
  593 https://doi.org:10.1038/s41576-022-00541-1
- Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and
  targeting genomes. *Nat Biotechnol* 32, 347-355 (2014).
  https://doi.org:10.1038/nbt.2842
- 597 37 Bothmer, A. *et al.* Characterization of the interplay between DNA repair and 598 CRISPR/Cas9-induced DNA lesions at an endogenous locus. *Nature* 599 *communications* **8**, 13905 (2017). https://doi.org:10.1038/ncomms13905
- 600 38 Choi, P. S. & Meyerson, M. Targeted genomic rearrangements using
  601 CRISPR/Cas technology. *Nature communications* 5, 3728 (2014).
  602 https://doi.org:10.1038/ncomms4728
- 603 39 Li, Y. *et al.* A versatile reporter system for CRISPR-mediated chromosomal
  604 rearrangements. *Genome Biol* 16, 111 (2015). <u>https://doi.org:10.1186/s13059-</u>
- 605 <u>015-0680-7</u>
- Maddalo, D. *et al.* In vivo engineering of oncogenic chromosomal
  rearrangements with the CRISPR/Cas9 system. *Nature* **516**, 423-427 (2014).
- 608 <u>https://doi.org:10.1038/nature13902</u>
- 41 Tao, Y. et al. Treatment of monogenic and digenic dominant genetic hearing

610		loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo. Nature
611		communications 14, 4928 (2023). https://doi.org:10.1038/s41467-023-40476-
612		Ζ
613	42	Binda, C. S., Klaver, B., Berkhout, B. & Das, A. T. CRISPR-Cas9 Dual-gRNA
614		Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA.
615		Viruses 12 (2020). https://doi.org:10.3390/v12030330
616	43	Salonia, F. et al. A dual sgRNA-directed CRISPR/Cas9 construct for editing
617		the fruit-specific beta-cyclase 2 gene in pigmented citrus fruits. Front Plant Sci
618		13, 975917 (2022). https://doi.org:10.3389/fpls.2022.975917
619	44	Blayney, J. et al. Unexpectedly High Levels of Inverted Re-Insertions Using
620		Paired sgRNAs for Genomic Deletions. <i>Methods Protoc</i> <b>3</b> (2020).
621		https://doi.org:10.3390/mps3030053
622	45	Nam, D. W. et al. Molecular Genetic Etiology and Revisiting the Middle Ear
623		Surgery Outcomes of Branchio-Oto-Renal Syndrome: Experience in a Tertiary
624		Referral Center. <i>Otol Neurotol</i> <b>44</b> , e319-e327 (2023).
625		https://doi.org:10.1097/MAO.000000000003880
626	46	Jiang, L., Wang, D., He, Y. & Shu, Y. Advances in gene therapy hold promise
627		for treating hereditary hearing loss. Mol Ther <b>31</b> , 934-950 (2023).
628		https://doi.org:10.1016/j.ymthe.2023.02.001
629	47	Peters, C. W. et al. Rescue of hearing by adenine base editing in a
630		humanized mouse model of Usher syndrome type 1F. Mol Ther 31, 2439-
631		2453 (2023). https://doi.org:10.1016/j.ymthe.2023.06.007

### 633 Figure legends

### Figure 1. Pedigrees, clinical phenotypes, and two novel *EYA1* SVs harboring BOR/BO syndrome

636 (a) Pedigree of the SNUH family with BOR/BO syndrome. The symbols in the 637 pedigree indicate the following: circle, female; square, male. (b) Schematic 638 representation illustrating the orientation and location of genomic segments 639 reconstructed with the complex genomic rearrangement (CGR). The genomic 640 coordinates of the breakpoints (depicted by red, blue, and green dotted vertical lines) 641 demarcate the junctions of the segments. The colors of the bars on the breakpoint 642 junction correspond to the following genomic positions: red, 71197433-71211857; 643 blue, 71211857-71228236; orange, 71228236-71548094. The coding sequence 644 configuration is depicted as connected segments. (c) Gap-PCR results align with the 645 breakpoints identified through WGS. Sanger sequencing verified the generated PCR 646 products. (d) The predicted effect of the EYA1 CGR on protein and domain structure. 647 The solid red arrow represents the position of the inverted exon 16 (e16), whereas 648 the dotted arrow denotes the position of the inverted exon 13 (e13). The 649 abbreviations used in the domain map are defined as follows: e, exon; ED, EYA 650 domain

651

Figure 2. Dual Cas9 nuclease mediated correction of EYA1 pathogenic
 complex

(a) Schematic representation of Cas9 nuclease and paired gRNA-mediatedcorrection of the pathogenic inversion. The dashed lines represent the Cas9 target

656 sites. (b) Schematic representation of the mature mRNA anticipated after correction 657 of the pathogenic inversion. (c) The Cas9 target sequences at the A-B junction and 658 B-C junction of the pathogenic EYA1 gene in patient fibroblasts. The protospacer 659 adjacent motif is highlighted in red. (d) Mutation frequencies induced by Cas9 660 nuclease at the A-B junction and B-C junction of the EYA1 gene. (e) Detection of 661 Cas9 nuclease-mediated inversions using inversion-specific primers. (f) Targeted 662 deep sequencing reads of amplicons generated using inversion-specific primers. (g) 663 Estimation of inversion frequencies by digital PCR analysis using serially diluted 664 samples. Diluted genomic DNA samples were subjected to PCR using inversion-665 specific primers. The results were analyzed using the Extreme Limiting Dilution 666 Analysis program (http://bioinf.wehi.edu.au/software/elda/).

667

### 668 **Figure 3. Restoration of EYA1 gene expression**

669 (a) Schematic workflow of digital droplet PCR (ddPCR). The genomic DNA was 670 subjected to amplification after partitioning into each droplet, see (a) and (b). Multiple 671 fluorescent signals were detected to fit into the Poisson distribution, see (c), to 672 calculate absolute concentration. (b) Primer and probe design. EYA1 wild-type and 673 complex SV-specific forward and reverse primers were used to verify the breakpoint 674 junction. (c) Two-dimensional plots of ddPCR results represent the EYA1 variant 675 allele frequency at each breakpoint junction. The colored dots in the 2D plot indicate 676 the following: gray, negative droplets; blue, droplets with mutant allele; green, 677 droplets with wild-type allele; orange, droplets with both mutant and wild-type alleles. 678 Genomic DNA was isolated from the EYA1 wild-type (control), EYA1 mutated

679 (patient), and EYA1-edited fibroblast cells.  $p < 0.01^{***}$  (n = 3, one-way analysis of 680 variance (ANOVA) followed by Bonferroni's multiple comparison test). (d) Wild-type 681 EYA1 transcript levels in both patient-derived and edited fibroblast cells. Quantitative 682 reverse transcription-polymerase chain reaction (qRT-PCR) analysis was performed, 683 and the GAPDH mRNA levels were used to normalize the levels of EYA1 expression. 684 Each bar represents the means of percent values (relative to the EYA1 mRNA levels 685 in wild-type fibroblast cells)  $\pm$  SEM from three independent experiments. (\*, p < 0.05; 686 \*\*, p < 0.01 one-way ANOVA with Bonferroni post hoc test) (e) Fibroblast cells were 687 concurrently transfected with an MYOG promoter-driven luciferase reporter and the 688 SIX1 wild-type construct. Relative luciferase activity (wild-type as control) was 689 plotted as mean  $\pm$  SEM (n = 3), \*, p < 0.05, \*\*,  $p < 0.01^{***}$ , p < 0.001 (one-way 690 ANOVA followed by Bonferroni's multiple comparison test). (f) Total RNA was 691 isolated, and the target genes (SOX2, GFI1, NEUROG1, and ATOH1) of EYA1 were 692 analyzed by qRT-PCR. GAPDH mRNA levels were used to normalize the results. 693 Values are represented as the mean  $\pm$  SEM of three independent experiments (N = 694 3); \*, *p* < 0.05, \*\*, *p* < 0.01, \*\*\*, *p* < 0.001 (n = 3, one-way ANOVA with Bonferroni's 695 multiple comparison test).

696

### **Figure 4. Designing a CRISPR activator strategy to elevate EYA1 levels**

(a) Relative *EYA1* transcript levels were determined by qRT-PCR. Fibroblast cells were treated with DMSO or CHX (50  $\mu$ g/mL) for 6h. All values were normalized to the untreated wild-type cells data and plotted as mean ± SEM (n = 3), \*\*\*, *p* < 0.001 (one-way ANOVA followed by Bonferroni's multiple comparison test). (b) (*left*)

702 HEK293T Cells were transfected with CRISPRa. Subsequently, gRT-PCR was used 703 to assess the expression of EYA1, and normalized to the expressions of the GAPDH 704 housekeeping gene. Data are presented as the mean  $\pm$  SEM (n = 3). (*right*) Graphical 705 depiction of EYA1 gene's promoter region including transcription start sites (TSS). 706 gRNA1–gRNA4 represent target sites of CRISPRa. (c) Schematic representation of 707 monoallelic and biallelic EYA1 KO cells with their genotypes. EYA1 708 haploinsufficiency was rescued using CRISPRa. (d) As in (b), except that dSaCas9-709 VP64 and either gRNA 2 or 3 were expressed in monoallelic and biallelic EYA1 710 knockout HEK293T cells, as well as wild-type HEK293T cells. Values represent 711 relative mRNA levels compared to HEK293 cells without transfection (control). (e) 712 The MYOG promoter-driven luciferase reporter and the SIX1 wild-type construct 713 were introduced into HEK293T cells and variants with either monoallelic or biallelic 714 EYA1 knockouts. Relative luciferase activity (relative to the HEK293T control) is 715 plotted as mean  $\pm$  SEM (n = 3), \*, p < 0.05, \*\*, p < 0.01 (one-way ANOVA followed by 716 Bonferroni's multiple comparison test). (f) As in (d), except that whole cell extracts 717 were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) followed by 718 immunoblotting (Upper). For quantification (Lower), signals from EYA1 were 719 normalized to those of beta-actin. Bars represent the mean  $\pm$  SEM. \*\*\*, p < 0.001720 (n=3, two-tailed Student's *t*-test).


721


Figure 5. Genomic landscape of disease-causing *EYA1* variants implicated in
 BOR/BO syndrome

(a) Circos plot (https://github.com/SNUH-hEARgeneLab/WGS\_analysis.) illustrating

the distribution of all reported disease-causing *EYA1* variants from the ClinVar
database. On the outer domain, the *EYA1* exons and corresponding reported
variants are depicted, while the inner domain displays the EYA domain (ED) of EYA1.
(b) Pie chart demonstrating the percentage of each variant type of *EYA1* diseasecausing variants associated with BOR/BO syndrome.

a







# U

wild-type


Complex SV














-C

e

a







 $\square$ 9

medRxiv preprint doi: https://doi.org/10.1101/2023.11.14.23298277; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Dosage		Cas9									
		AB-T1/BC-T2					A	<mark>∖</mark> Β-Τ	<sup>-</sup> 1/BC-	Т3	
pg		Test	ed	Response			Tested	d Res		sponse	
66		24	4	3			24			3	
660		4	8	22			48		38		
3300		1	2	12			12		12		
Types		AB-T1/BC-T2					A	∖B-T	3-T1/BC-T3		
1,9000	Lov	ver	Estimat	е	Upper		Lower	Est	imate	Upper	
Cas9	0.48% 0.6		0.69%	%	1.00%		1.11%	1.	55%	2.16%	



17

17

17

16

13

16

## A-B junction

AB-T1 5'-CTTGTAAAACTCCTTCTCAAATAAATGTCTTAG<mark>AGG</mark>AGAGAATTTTTT-3' 3'-GAACATTTTGAGGAAGAGTTTATTTACAGAATCTCCTCTTTAAAAAA-5'

## **B-C** junction

5'-GGCTAACGTTAAGACCAGGGCATTTTAGGTGGGTCTGAAATTCCA-3' 3'-CCGATTGCAATTCT<mark>GGT</mark>CCCGTAAAATCCACCCAGACTTTAAGGT-5' BC-T3

TCTGATGTAGTCTTGTAAAACTCCT**TCTCAAATAAATGTCT-TAGAGG**AGAGAATTTTTTGAGTAGG TCTGATGTAGTCTTGTAAAACTCCTTCTCAAATAAATGTCT-TAGAGGAGAGAAATTTTTTGAGTAGG

TCTGATGTAGTCTTGTAAAACTCCTTCTCAAATAAATGTCTtTAGAGGAGAGAGAATTTTTTGAGTAGG TCTGATGTAGTCTTGTAAAACTCCTTCTCAAATAAATGTC--TAGAGGAGAGAAATTTTTTGAGTAGG

TCTGATGTAGTCTTGTAAAACTCCTT-----TTTTGAGTAGG

ATTTTACTTGACTGGCTAACGTTAAGACCAGGGCAT-TTTAGGTGGGTCTGAAATTCCACCACAC ATTTTACTTGACTGGCTAACGTTAAGACCAGGGCAT-TTTAGGTGGGTCTGAAATTCCACCACAC ATTTTACTTGACTGGCTAACGTTAAGACCAGGGCATtTTAGGTGGGTCTGAAATTCCACCACAC ATT-----CCACCACAC

ATTTTACTTGACTGGCTAACGTTAAGACCAGGGCA--TTTAGGTGGGTCTGAAATTCCACCACAC ATTT-----

SACCCACCTAAAATGCCCTGGTCTTAACGTTAGCCA	WT
GACCCACCTAAAAT-CCCTGGTCTTAACGTTAGCCA	24.67%
GACCCACCTAAAAT <mark>g-</mark> CCTGGTCTTAACGTTAGCCA	6.66%
GACCCACCTAAAATGGTCTTAACGTTAGCCA	4.59%
GACCCACCTGGTCTTAACGTTAGCCA	4.25%
GACCCACCCTGGTCTTAACGTTAGCCA	3.72%




B (16 kb)	C
AB-T1/BC-T2	
CTTGTAAAACTCCTTCTCAAATAAATGACCTAAAATGCCCTGGTCTTAACGTTA	
A	00.00/
CTTGTAAAACTCCTTCTCAAATAAATG-TCTAAAATGCCCTGGTCTTAACGTTA CTTGTAAAACTCCTTCCTCAAATAAATG-TCTAAAATGCCCCTGGTCTTAACGTTA	
CTTGTAAAACTCCTTCTCAAATAAATGTCTATGCCCTGGTCTTAACGTTA CTTGTAAAACTCCTTCTCAAATAAATGTCTAAATGCCCTGGTCTTAACGTTA	
CITGIAAACICCIICICAAAIAAAIGIC <sup></sup> IAAAIGCCCIGGICIIAACGIIA	9.070
AB-T1/BC-T3	
TAAAACTCCTTCTCAAATAAATGACCTAAAATGCCCTGGTCTTAACGTTAGCCA	
A	
TAAAACTCCTTCTCAAATAAATG <mark>T</mark> CTCCCTGGTCTTAACGTTAGCCA	51.2%
TAAAACTCCTTCTCAAATAAATG <mark>T</mark> C	9.4%
TAAAACTCCTTCTCAAATAAATGTGGTCTTAACGTTAGCCA	4.8%

### AB-T2




GAAAGTGCCCCTCCAAGGTCCTCTCC	WT
GAAAGTGCCCCTCCAAGGTCCTCTCC	53.5%
CTCC	22.5%
GAAAGTGCCCCTCCAAGGTCCTCTCC	3.03%
AAGGTCCTCTCC	2.28%
GAAAGTGCCCCTCCAAGGTCCTCTCC	1.92%
GAAAGTGCCCCTCCAAGGTCCTCTCC	1.05%


CAAAATCATCCCTTCTGAATCTTCTT	WT
CAAAATCATCCCTTCTGAATCTTCTT	9.75%
CAAAATCATCCCTTCTGAATCTTCTT	8.98
CAAAATCATCCCTTCTGAATCTTCTT	8.06%
CAAAATCATCCCTTCTGAATCTTCTT	7.15%
CTT	6.94%




(a) Sample genomic DNA


(b) Droplet amplification







## (C) Detection & Fitting







ATOH1





С








Monoallelic KO/CRISPRa

CCTATGCCACGTACCCAC-AGCCAGGACA


AGA**GAACTGGTGAGTTGGTCGTGGG**CTG



















dSaCas9-VP64






Lp.Pro133HisfsTer14

p.Gln156Ter

(~72211317)\_(72226125\_?)del



# Percentage of variant type